Sanofi's Breakthrough in China with Qfitlia and Cablivi Approvals

The National Medical Products Administration (NMPA) of China has approved Sanofi's Qfitlia and Cablivi for rare hematologic diseases. Qfitlia, an antithrombin-lowering therapy, is designed to prevent bleeding in hemophilia patients with just six injections annually. Cablivi targets acquired thrombotic thrombocytopenic purpura (aTTP), a rare blood clotting disorder.

These approvals mark Sanofi's fourth and fifth in China for 2025. Qfitlia's approval follows significant clinical success demonstrated in ATLAS phase 3 trials, showcasing a 71% reduction in bleeding episodes for patients without inhibitors. Meanwhile, Cablivi's approval is significant for China's estimated 2,700 annual aTTP cases, promising improved management of this condition.